Table 1.

Baseline cardiac functions before ischemia in control, untreated hearts and hearts subsequently treated with NAG-thiazolines during reperfusion

Groups	n	Coronary Flow, ml/min	Heart Rate, beats/min	LVDP, mmHg	+dP/dt, mmHg/s	−dP/dt, mmHg/s	RPP, mmHg/min
Control	6	10.1 ± 0.7	324 ± 13	96.6 ± 10.0	3,374 ± 174	2,166 ± 308	30,688 ± 1,725
NBt50	7	12.3 ± 0.9	323 ± 9	89.9 ± 9.9	3,451 ± 313	2,078 ± 253	28,905 ± 2,881
NBt100	5	13.2 ± 0.9	335 ± 18	83.6 ± 6.5	3,428 ± 259	1,966 ± 146	27,744 ± 1,610
NAe	3	14.2 ± 1.0	359 ± 29	74.6 ± 5.5	3,930 ± 375	1,796 ± 125	27,029 ± 3,596

Values are means ± SE ; n, no. of replicates/group, LVDP, left ventricular developed pressure; +dP/dt, maximum rate of change in left ventricular pressure; −dP/dt, minimum rate of change in left ventricular pressure; RPP, rate-pressure product. Baseline cardiac function was assessed after 30 min normoxic equilibration before 20 min zero-flow ischemia. There were no significant differences in preischemic cardiac parameters between untreated, ischemia-reperfusion hearts (control) and hearts treated with 50 μM 1,2 dideoxy-2′-propyl-α-d-glycopyranoso-[2,1-d]-Δ2′-thiazoline [NAG-Bt (NBt50)], 100 μM NAG-Bt (NBt100), and 50 μM 1,2 dideoxy-2′-ethylamino-α-d-glucopyranoso-[2,1-d]-Δ2′-thiazoline (NAe).